On February 22, 2021 Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS) therapies, reported that the Ministry of Food and Drug Safety (MFDS) of Korea has approved its Phase 1/2 clinical study application for CRC01, CD19 CAR-T cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma(DLBCL) (Press release, Curocell, FEB 22, 2021, View Source [SID1234575408]). This study is expected to be initiated in the first half of 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to receive Korea’s first IND clearance for a CAR-T therapy," said Gunsoo Kim, CEO of Curocell. "OVIS is a unique CAR-T platform that combines CAR-T with immune checkpoint receptor inhibition. This unique technology can be a breakthrough for patients who are difficult to treat with conventional CD19 CAR-T."

About CRC01

CRC01, recognized CD19 and is based on OVIS, a first in class CAR-T platform co-developed with KAIST. OVIS downregulates PD1 and TIGIT in the same viral vector, designed to express a CAR protein, allowing cost-effective and simple manufacturing. Curocell holds the global development and commercial rights for CRC01 and OVIS.